Seattle researchers unveil $95 million AI biology initiative to map nature’s design rules

Seattle scientists have announced a new $95 million effort that uses artificial intelligence to decode the design principles of biological molecules. The project, led by Nobel laureate David Baker, aims to create a computational platform that can predict how proteins and other biomolecules fold and function, potentially accelerating drug discovery.

The initiative brings together expertise from chemistry, biology, and computer science and is expected to generate open‑source tools for the broader research community. Funding will support the development of large‑scale models and the training of a multidisciplinary team over the next several years.

In the same roundup, Ultragenyx reported a setback as its Angelman syndrome drug failed to meet primary endpoints in a pivotal Phase 3 trial. The company said it will reassess its development strategy. The FDA also highlighted recent actions to curb the marketing of unproven stem cell therapies, reinforcing its regulatory oversight.

These mixed developments underscore both the challenges of advancing novel therapies and the growing investment in AI‑driven biology as a way to improve success rates in the biotech sector.